Production (Stage)
BridgeBio Pharma, Inc.
BBIO
$40.07
-$1.07-2.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.83% | -63.57% | -120.59% | -108.59% | 79.06% |
| Total Depreciation and Amortization | -6.07% | -11.12% | -2.29% | -1.38% | 0.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.91% | 409.18% | 82.05% | -354.20% | 98.75% |
| Change in Net Operating Assets | -997.38% | 704.34% | -100.87% | 209.43% | -1,124.61% |
| Cash from Operations | -2.00% | -8.17% | -341.71% | 134.03% | -75.88% |
| Capital Expenditure | -- | 65.69% | -153.70% | 92.23% | -59.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 100.00% | 57.14% | -- | -- |
| Other Investing Activities | 50.00% | -108.31% | 1,103.54% | -86.39% | 6,254.47% |
| Cash from Investing | 50.73% | -108.47% | 1,157.85% | -86.64% | 34,574.24% |
| Total Debt Issued | 15.00% | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | 102.18% | 32.47% | -- | -- | 95,442.04% |
| Repurchase of Common Stock | -3,464.96% | 2.70% | 27.74% | 31.98% | -14.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 58.65% | -- | 100.00% | 69.54% | -432.55% |
| Cash from Financing | -87.27% | 66,934.09% | 112.34% | -102.05% | 6,280.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -151.02% | 294.42% | -296.68% | -12.99% | 163.96% |